Welcome to our dedicated page for Quoin Pharmaceuticals SEC filings (Ticker: QNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quoin Pharmaceuticals Ltd. (QNRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Quoin is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, and its filings offer detailed insight into clinical development plans, financing structures, governance decisions and risk factors relevant to investors.
Among the most informative documents for QNRX are its periodic reports and current reports on Form 8-K. Recent 8-K filings describe key events such as private placement financings involving American Depositary Shares, pre-funded warrants and multiple series of warrants tied to milestones for the lead asset, QRX003, including pivotal trial outcomes and potential FDA approval. Other 8-Ks outline regulatory milestones, including Orphan Drug Designation and Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome, as well as corporate actions like equity incentive plan approvals, changes in executive leadership and amendments to the company’s articles of association.
For users interested in the clinical and regulatory trajectory of Quoin’s programs, filings referenced to press releases detail the status of late-stage pivotal trials for QRX003, investigator-led pediatric studies and the development of topical rapamycin delivery technologies targeting microcystic lymphatic malformations and venous malformations. These documents also include the company’s cautionary statements about forward-looking information, highlighting uncertainties around clinical trial results, regulatory approvals, funding needs and operational risks.
Stock Titan enhances this information by pairing real-time EDGAR updates with AI-powered summaries that explain the significance of each filing in clear language. Users can quickly understand the core points of complex agreements, equity incentive plans, financing terms and clinical disclosures without reading every page of the original document. In addition, the filings page makes it easier to monitor governance items such as compensation policies, lock-up agreements and shareholder meeting results, all of which can influence the risk–reward profile of QNRX for market participants.
Quoin Pharmaceuticals, Ltd. reported a Form 4 filing by Stonepine Capital Management, LLC, identified as a ten percent owner of QNRX. The summarized data shows no reported purchases, sales, exercises, gifts, or other share transactions in this filing.
Quoin Pharmaceuticals Ltd. is a late-stage clinical specialty pharma company focused on rare genetic skin diseases, led by QRX003 for Netherton Syndrome. The therapy is in multiple Phase 2 studies under an open FDA IND and has shown meaningful itch and skin-score improvements in very small patient groups, including a pediatric case rated clear after 12 months.
QRX003 holds Orphan Drug, Rare Pediatric Disease and Fast Track designations from the FDA, plus Orphan status in Europe, and the company has applied for Saudi Breakthrough Medicine and Japanese Orphan Drug designations. A recent FDA Type C meeting indicated a single Phase 3 trial may support U.S. approval.
Quoin has no approved products or revenue and reported an accumulated deficit of about $71.0 million as of December 31, 2025, with cash and cash equivalents of $3.8 million and investments of $14.9 million. Management and auditors note substantial doubt about its ability to continue as a going concern without additional capital.
Quoin Pharmaceuticals reported fourth quarter and full-year 2025 results alongside a substantial corporate and regulatory update. For the year ended December 31, 2025, net loss was approximately $15.8 million compared to $9.0 million in 2024, reflecting higher research and development and general and administrative spending. Net loss for the quarter ended December 31, 2025 was about $4.3 million versus $2.3 million a year earlier. Quoin held roughly $18.7 million in cash, cash equivalents and marketable securities at year-end and believes this will fund operations into 2027.
Strategically, Quoin closed a private placement financing of up to $104.5 million in October 2025, including $16.5 million at closing and up to $88.0 million from potential warrant exercises. The company secured Orphan Drug Designations for lead candidate QRX003 for Netherton Syndrome in the U.S. and Europe and obtained U.S. Fast Track Designation in March 2026. A recent Type C meeting indicated that a single Phase 3 trial may support U.S. approval, with Phase 3 initiation and full enrollment targeted for 2026 and a potential NDA filing in 2027. Quoin is also expanding studies in Peeling Skin Syndrome and advancing topical rapamycin programs with proof-of-concept trials planned for the second half of 2026.
Quoin Pharmaceuticals Ltd. filed a report describing that the U.S. Food and Drug Administration has granted Fast Track Designation to its investigational QRX003 lotion (4%) for the treatment of Netherton Syndrome, a rare and severe genetic skin disease with no approved therapies.
The company explains that Fast Track status is intended to speed development and review of drugs for serious conditions with unmet medical need. QRX003 is already in two late-stage whole-body clinical trials and has previously received Orphan Drug and Pediatric Rare Disease designations in the U.S., as well as Orphan Drug Designation in Europe.
Quoin Pharmaceuticals, Ltd. reported Schedule 13G ownership disclosures for certain ADAR1-related parties. The filing shows ADAR1 Capital Management, LLC and Daniel Schneeberger each beneficially hold 58,230 American Depositary Shares (ADS), representing 6.9% of the class as of December 31, 2025. The filing states ADAR1 Capital Management GP, LLC beneficially holds 50,226 ADS (6.0%). These figures are reported based on 838,976 ADS outstanding as of November 3, 2025 as disclosed in the company prospectus. The disclosure also notes excluded amounts of ADS underlying warrants that are subject to a 4.99% beneficial ownership limitation.
Quoin Pharmaceuticals shareholder Woodline Partners has disclosed a significant passive stake in the company. Woodline Partners LP, an investment adviser, reports beneficial ownership of 2,785,370 Ordinary Shares of Quoin, representing 9.5% of the class, with sole voting and dispositive power over all reported shares.
The position is held through Woodline Master Fund LP via American Depositary Shares, each representing thirty-five Ordinary Shares. The percentage ownership is based on 29,364,180 Ordinary Shares outstanding as of November 3, 2025. Woodline certifies the holdings are in the ordinary course of business and not for the purpose of influencing control of Quoin Pharmaceuticals.
A group of investment entities associated with Israel A. Englander, including Integrated Core Strategies (US) LLC and Millennium Management LLC, reports beneficial ownership of 2,618,595 Quoin Pharmaceuticals ordinary shares, representing 4.6% of the class as of December 31, 2025.
The group reports only shared voting and dispositive power over these shares and no sole power. They state they have ceased to be beneficial owners of more than 5% of the outstanding ordinary shares and certify that the holdings are not for the purpose of influencing control of Quoin Pharmaceuticals.
Ikarian Capital, LLC and Neil Shahrestani filed an amended Schedule 13G reporting their beneficial ownership of 211,538 American Depositary Shares (ADS) of Quoin Pharmaceuticals, Ltd., equal to 12.6% of the ADS class based on 1,683,627 ADS outstanding as of January 31, 2026.
The ADS represent ordinary shares of Quoin and are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts over which Ikarian Capital has investment discretion. The filers state the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Quoin.
Quoin Pharmaceuticals (QNRX) reported a new stock option grant to its Chief Financial Officer, Sally Bridget Lawlor. On February 4, 2026, she received an option to purchase 85,250 American Depositary Shares (ADS) at an exercise price of $7.37 per ADS.
The option covers ADSs, each representing thirty-five ordinary shares of Quoin Pharmaceuticals. The award vests over four years, with 20% vesting on each of February 4, 2027, 2028 and 2029, and the remaining 40% vesting on February 4, 2030. The option expires on February 4, 2036 and is held directly by the CFO.
Quoin Pharmaceuticals director Joseph Patrick Cooper reported receiving a new stock option grant. On February 4, 2026, he was awarded options to acquire 8,141 American Depositary Shares at an exercise price of $7.37 per ADS. Each ADS represents thirty-five ordinary shares of Quoin Pharmaceuticals.
The options vest over four years, with 20% becoming exercisable on each of February 4, 2027, 2028, and 2029, and the remaining 40% vesting on February 4, 2030. After this grant, Cooper beneficially owns 8,141 derivative securities directly.